Clinical trial with Corynebacterium parvum.

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Malignant tumors often necessitate aggressive treatments like chemotherapy.
• Chemotherapy can suppress the immune system, complicating treatment efficacy.
• Immunomodulatory agents are explored to counteract chemotherapy-induced immunosuppression.

Purpose of the Study:

• To evaluate the immunomodulatory effects of Corynebacterium parvum in cancer patients receiving chemotherapy.
• To assess the safety and tolerability of Corynebacterium parvum administration in this patient population.

Main Methods:

• Sixteen patients with malignant tumors undergoing repeated chemotherapy courses received Corynebacterium parvum injections.
• Dosing involved 3.5 mg/m2 administered weekly, biweekly, or monthly between chemotherapy cycles.
• Immune responses were monitored through lymphocyte stimulation tests (PHA), skin antigen reactivity, and clinical observations.

Main Results:

• Corynebacterium parvum administration induced systemic side effects including fever and local pain in most patients.
• Peripheral and bone-marrow monocytic infiltration and splenomegaly were observed.
• Lymphocyte stimulation by PHA initially decreased but subsequently increased, indicating enhanced immune activity.
• Cutaneous reactivity to antigens improved, with negative pre-treatment tests becoming positive post-treatment.

Conclusions:

• Corynebacterium parvum demonstrates immunomodulatory potential in cancer patients undergoing chemotherapy.
• The observed immune enhancements suggest a possible role for Corynebacterium parvum in combination cancer therapy.
• Further research is warranted to optimize its use and manage associated side effects.